Working Groups
Net4Brain's six working groups form one translational pipeline — WG1 to WG5 run from non-invasive biomarkers and preclinical models through tumour profiling and AI modelling to clinical recommendations, while WG6 cuts across them all to maximise dissemination and impact.
One translational pipeline
Explore what each working group is doing and who leads it.
WG1
WG1. Non-invasive Biomarker Discovery
Discovering sensitive and specific liquid-biopsy and radiomics biomarkers for early detection, prognosis and recurrence monitoring of brain cancer.
Leader: Prof Aida Hajdarpasic
Explore WG1WG2
WG2. Preclinical Modelling
Development of more accurate GEMMs and PDOX models, plus 3D systems — neurospheres, organoids and bioprinting — to understand brain tumour mechanisms.
Leader: Prof Anna Golebiewska
Explore WG2WG3
WG3. Pathogenesis and Tumour Profiling
Unravelling brain cancer pathogenesis through single-cell and multi-omics profiling for patient stratification and treatment optimisation.
Leader: Prof Tugba Bagci-Onder
Explore WG3WG4
WG4. Mathematical & Computational Modelling
Integrating multi-omics and radiomics data with AI/ML and mathematical modelling to advance precision medicine and AI-guided practice.
Leader: Prof Claudio Angione
Explore WG4WG5
WG5. Clinical Treatment Recommendation
Advancing radiotherapy through radiomics and multimodal -omics, refining pathological grading and personalising treatment for low- and high-risk patients.
Leader: Dr Alkinoos Athanasiou
Explore WG5WG6
WG6. Dissemination and Exploitation
Maximising the impact of Action outputs through communication, outreach, exploitation and training, and the home of the Creative Group.
Leader: Dr Aylin Toplu
Explore WG6Bench to bedside
Each working group feeds the next: biomarkers and preclinical models deepen our understanding of tumour biology, whose profiling powers the AI and mathematical models, and those models turn into clinical treatment recommendations. Dissemination and exploitation work across the whole pipeline so findings reach clinicians, patients and the public.
Get involved
Working groups welcome active contributions from Action members. Join a group and shape its next steps.